Vitamin E (mixed tocotrienols)

Proprietary Source

EVNol SupraBio™ by Excelvite extracted from sustainable Malaysian red palm fruit oil

Chemical Name


Immune support

Tocotrienols improve cell-mediated immune response and are 40-60 times stronger antioxidant than alpha-tocopherol (regular vitamin E) 

Other uses

Tocotrienols also seem to benefit people with a genetic disorder called familial dysautonomia by increasing levels of a certain protein in blood cells. Tocotrienols might lower cholesterol levels and provide heart health benefits. Nanomolar concentration prevents glutamate-induced neurotoxicity. Slows down progression of white matter lesions. Attenuates non-alcoholic fatty liver disease (NAFLD). Mitigates liver stiffness, maintains healthy liver function, and maintains healthy lipid profile, cholesterol level. When it comes to heart health, tocotrienols can mitigate atherosclerosis in carotid stenosis, support arterial compliance, and work as potent antioxidants in preventing LDL oxidation. They also improve skin characteristics, surgical scar treatment, speed wound healing, and promote hair growth. 

How it works

Tocotrienols exist in four different forms: alpha-, beta-, gamma-, and delta-tocotrienols and seem to have many different effects in the body including causing an improved cell-mediated immune response and super vitamin E antioxidant effects. 


Tocotrienols are safe when taken by mouth. Tocotrienols have been used safely in clinical trials at doses of up to 600 mg daily for 3 months. Tocotrienols have also been used safely at a dose of 200 mg daily for up to 5 years.

When applied to the skin: There isn't enough reliable information to know if tocotrienols are safe when applied to the skin. In some people, tocotrienol cream can cause mild itching.

Special Precautions & Warnings:

Pregnancy and breast-feeding: There isn't enough reliable information to know if it is safe to use tocotrienols when pregnant or breast-feeding. Stay on the safe side and avoid use.

Diabetes: Tocotrienols might lower blood sugar levels. People with diabetes should monitor their blood glucose levels closely. If you have diabetes, it's best to check with your healthcare provider before starting tocotrienols.

Surgery: Tocotrienols might affect blood sugar levels, so there is a concern that it might interfere with blood sugar control during and after surgery. Stop using tocotrienols at least 2 weeks before a scheduled surgery.

Interactions with medications

Medications for diabetes (Antidiabetes drugs)

Interaction Rating = Moderate Be cautious with this combination.

Talk to your health provider.

Some research shows that tocotrienols might decrease blood sugar in people with type 2 diabetes. However, conflicting evidence exists. Until more is known, use cautiously in combination with antidiabetes drugs. In theory, taking tocotrienols along with diabetes medications might cause blood sugar levels to drop too low. Monitor your blood sugar closely if you take tocotrienols. The dose of your diabetes medication might need to be changed.

Some medications used for diabetes include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, pioglitazone (Actos), rosiglitazone (Avandia), and others.

Interactions with Herbs, Supplements, and Foods

Herbs and supplements that might lower blood sugar

Tocotrienols might lower blood sugar. However, conflicting evidence exists. Until more is known, use cautiously in combination with other herbs and supplements that might lower blood sugar. Using tocotrienols along with other herbs and supplements that have the same effect might cause blood sugar to drop too low in some people. Some of these products include devil's claw, fenugreek, guar gum, Panax ginseng, Siberian ginseng, and others.

There are no known interactions with foods.


Mensink RP, van Houwelingen AC, Kromhout D, Hornstra G. A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Am J Clin Nutr 1999;69:213-9.

Qureshi AA, Qureshi N, Wright JJ, et al. Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). Am J Clin Nutr 1991;53:1021S-6S.

Qureshi AA, Bradlow BA, Brace L, et al. Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids 1995;30:1171-7.

Baumann LS, Spencer JS. The effects of topical vitamin E on the cosmetic appearance of scars. Dermatol Surg 1999;25:311-5.

Nesaretnam K, Ambra R, Selvaduray KR, et al. Tocotrienol-rich fraction from palm oil affects gene expression in tumors resulting from MCF-7 cell inoculation in athymic mice. Lipids 2004;39:459-67.

Nesaretnam K, Ambra R, Selvaduray KR, et al. Tocotrienol-rich fraction from palm oil and gene expression in human breast cancer cells. Ann N Y Acad Sci 2004;1031:143-57.

Agarwal MK, Agarwal ML, Athar M, Gupta S. Tocotrienol-rich fraction of palm oil activates p53, modulates Bax/Bcl2 ratio and induces apoptosis independent of cell cycle association. Cell Cycle 2004;3;205-11.

Schaffer, S., Muller, W. E., and Eckert, G. P. Tocotrienols: constitutional effects in aging and disease. J Nutr 2005;135(2):151-154.

Nesaretnam, K., Stephen, R., Dils, R., and Darbre, P. Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. Lipids 1998;33(5):461-469.

Sen, C. K., Khanna, S., and Roy, S. Tocotrienol: the natural vitamin E to defend the nervous system? Ann N Y Acad Sci 2004;1031:127-142.

Das, S., Nesaretnam, K., and Das, D. K. Tocotrienols in cardioprotection. Vitam Horm 2007;76:419-433.

van Haaften, R. I., Haenen, G. R., Evelo, C. T., and Bast, A. Tocotrienols inhibit human glutathione S-transferase P1-1. IUBMB Life 2002;54(2):81-84.

Suarna, C., Hood, R. L., Dean, R. T., and Stocker, R. Comparative antioxidant activity of tocotrienols and other natural lipid-soluble antioxidants in a homogeneous system, and in rat and human lipoproteins. Biochim Biophys Acta 1993;1166(2-3):163-170.

Chao, J. T., Gapor, A., and Theriault, A. Inhibitory effect of delta-tocotrienol, a HMG CoA reductase inhibitor, on monocyte-endothelial cell adhesion. J Nutr Sci Vitaminol (Tokyo) 2002;48(5):332-337.

O'Byrne, D., Grundy, S., Packer, L., Devaraj, S., Baldenius, K., Hoppe, P. P., Kraemer, K., Jialal, I., and Traber, M. G. Studies of LDL oxidation following alpha-, gamma-, or delta-tocotrienyl acetate supplementation of hypercholesterolemic humans. Free Radic Biol Med 2000;29(9):834-845.

Parker, R. A., Pearce, B. C., Clark, R. W., Gordon, D. A., and Wright, J. J. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 1993;268(15):11230-11238.

Song, B. L. and DeBose-Boyd, R. A. Insig-dependent ubiquitination and degradation of 3-hydroxy-3-methylglutaryl coenzyme a reductase stimulated by delta- and gamma-tocotrienols. J Biol Chem 2006;281(35):25054-25061.

Guthrie, N., Gapor, A., Chambers, A. F., and Carroll, K. K. Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. J Nutr 1997;127(3):544S-548S.

Wada, S., Satomi, Y., Murakoshi, M., Noguchi, N., Yoshikawa, T., and Nishino, H. Tumor suppressive effects of tocotrienol in vivo and in vitro. Cancer Lett 2005;229(2):181-191.

Naguib, Y., Hari, S. P., Passwater, R., Jr., and Huang, D. Antioxidant activities of natural vitamin E formulations. J Nutr Sci Vitaminol (Tokyo) 2003;49(4):217-220.

Fuchs, J., Weber, S., Podda, M., Groth, N., Herrling, T., Packer, L., and Kaufmann, R. HPLC analysis of vitamin E isoforms in human epidermis: correlation with minimal erythema dose and free radical scavenging activity. Free Radic Biol Med 2003;34(3):330-336.

Weng-Yew, W., Selvaduray, K. R., Ming, C. H., and Nesaretnam, K. Suppression of tumor growth by palm tocotrienols via the attenuation of angiogenesis. Nutr Cancer 2009;61(3):367-373.

Hussein, D. and Mo, H. d-δ-tocotrienol-mediated suppression of the proliferation of human PANC-1, MIA PaCa-2, and BxPC-3 pancreatic carcinoma cells. Pancreas 2009;38(4):e124-e136.

Elangovan, S., Hsieh, T. C., and Wu, J. M. Growth inhibition of human MDA-mB-231 breast cancer cells by delta-tocotrienol is associated with loss of cyclin D1/CDK4 expression and accompanying changes in the state of phosphorylation of the retinoblastoma tumor suppressor gene product. Anticancer Res 2008;28(5A):2641-2647.

Sun, W., Wang, Q., Chen, B., Liu, J., Liu, H., and Xu, W. Gamma-tocotrienol-induced apoptosis in human gastric cancer SGC-7901 cells is associated with a suppression in mitogen-activated protein kinase signalling. Br J Nutr 2008;99(6):1247-1254.

Ahn, K. S., Sethi, G., Krishnan, K., and Aggarwal, B. B. Gamma-tocotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. J Biol Chem 2007;282(1):809-820.

Nesaretnam, K., Guthrie, N., Chambers, A. F., and Carroll, K. K. Effect of tocotrienols on the growth of a human breast cancer cell line in culture. Lipids 1995;30(12):1139-1143.

Yu, W., Simmons-Menchaca, M., Gapor, A., Sanders, B. G., and Kline, K. Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. Nutr Cancer 1999;33(1):26-32.

Nesaretnam, K., Dorasamy, S., and Darbre, P. D. Tocotrienols inhibit growth of ZR-75-1 breast cancer cells. Int J Food Sci Nutr 2000;51 Suppl:S95-103.

Takahashi, K. and Loo, G. Disruption of mitochondria during tocotrienol-induced apoptosis in MDA-MB-231 human breast cancer cells. Biochem Pharmacol 2004;67(2):315-324.

Sylvester, P. W., Nachnani, A., Shah, S., and Briski, K. P. Role of GTP-binding proteins in reversing the antiproliferative effects of tocotrienols in preneoplastic mammary epithelial cells. Asia Pac J Clin Nutr 2002;11 Suppl 7:S452-S459.

Goh, S. H., Hew, N. F., Norhanom, A. W., and Yadav, M. Inhibition of tumour promotion by various palm-oil tocotrienols. Int J Cancer 1994;57(4):529-531.

Naito, Y., Shimozawa, M., Kuroda, M., Nakabe, N., Manabe, H., Katada, K., Kokura, S., Ichikawa, H., Yoshida, N., Noguchi, N., and Yoshikawa, T. Tocotrienols reduce 25-hydroxycholesterol-induced monocyte-endothelial cell interaction by inhibiting the surface expression of adhesion molecules. Atherosclerosis 2005;180(1):19-25.

Zhou, C., Tabb, M. M., Sadatrafiei, A., Grun, F., and Blumberg, B. Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. Drug Metab Dispos 2004;32(10):1075-1082.

Rubin, B. Y., Anderson, S. L., and Kapas, L. Can the therapeutic efficacy of tocotrienols in neurodegenerative familial dysautonomia patients be measured clinically? Antioxid Redox Signal 2008;10(4):837-841.

Anderson, S. L., Qiu, J., and Rubin, B. Y. Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia. Biochem Biophys Res Commun 2003;306(1):303-309.

Hayes, K. C., Pronczuk, A., and Liang, J. S. Differences in the plasma transport and tissue concentrations of tocopherols and tocotrienols: observations in humans and hamsters. Proc Soc Exp Biol Med 1993;202(3):353-359.

Schwedhelm, E., Maas, R., Troost, R., and Boger, R. H. Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. Clin Pharmacokinet 2003;42(5):437-459.

Yap, S. P. and Yuen, K. H. Influence of lipolysis and droplet size on tocotrienol absorption from self-emulsifying formulations. Int J Pharm 2004;281(1-2):67-78.

Lodge, J. K., Ridlington, J., Leonard, S., Vaule, H., and Traber, M. G. Alpha- and gamma-tocotrienols are metabolized to carboxyethyl-hydroxychroman derivatives and excreted in human urine. Lipids 2001;36(1):43-48.

Sontag, T. J. and Parker, R. S. Influence of major structural features of tocopherols and tocotrienols on their omega-oxidation by tocopherol-omega-hydroxylase. J Lipid Res 2007;48(5):1090-1098.

Fairus, S., Nor, R. M., Cheng, H. M., and Sundram, K. Postprandial metabolic fate of tocotrienol-rich vitamin E differs significantly from that of alpha-tocopherol. Am J Clin Nutr 2006;84(4):835-842.

Khosla, P., Patel, V., Whinter, J. M., Khanna, S., Rakhkovskaya, M., Roy, S., and Sen, C. K. Postprandial levels of the natural vitamin E tocotrienol in human circulation. Antioxid Redox Signal 2006;8(5-6):1059-1068.

Qureshi, A. A., Sami, S. A., Salser, W. A., and Khan, F. A. Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans. Atherosclerosis 2002;161(1):199-207.

Aggarwal BB, Sundaram C, Prasad S, Kannappan R. Tocotrienols, the vitamin E of the 21st century: Its potential against cancer and other chronic diseases. Biochem Pharmacol 2010;80(11):1613-1631.

Choudhury, N., Tan, L., and Truswell, A. S. Comparison of palmolein and olive oil: effects on plasma lipids and vitamin E in young adults. Am J Clin Nutr 1995;61(5):1043-1051.

Mustad, V. A., Smith, C. A., Ruey, P. P., Edens, N. K., and DeMichele, S. J. Supplementation with 3 compositionally different tocotrienol supplements does not improve cardiovascular disease risk factors in men and women with hypercholesterolemia. Am J Clin Nutr 2002;76(6):1237-1243.

Baliarsingh, S., Beg, Z. H., and Ahmad, J. The therapeutic impacts of tocotrienols in type 2 diabetic patients with hyperlipidemia. Atherosclerosis 2005;182(2):367-374.

Daud ZA, Tubie B, Sheyman M, et al. Vitamin E tocotrienol supplementation improves lipid profiles in chronic hemodialysis patients. Vasc Health Risk Manag. 2013;9:747-61.

Shen CL, Wang S, Yang S, et al. A 12-week evaluation of annatto tocotrienol supplementation for postmenopausal women: safety, quality of life, body composition, physical activity, and nutrient intake. BMC Complement Altern Med. 2018 Jun 28;18(1):198.

Pervez MA, Khan DA, Ijaz A, Khan S. Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease. Turk J Gastroenterol. 2018 Mar;29(2):170-176.

Mahipal A, Klapman J, Vignesh S, et al. Pharmacokinetics and safety of vitamin E d-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites. Cancer Chemother Pharmacol. 2016 Jul;78(1):157-65. Epub 2016 Jun 8.

Meganathan P, Jabir RS, Fuang HG, et al. A new formulation of Gamma Delta Tocotrienol has superior bioavailability compared to existing Tocotrienol-Rich Fraction in healthy human subjects. Sci Rep. 2015 Sep 1;5:13550.

Schuchardt JP, Heine S, Hahn A. A combination of palm oil tocotrienols and citrus peel polymethoxylated flavones does not influence elevated LDL cholesterol and high-sensitivity C-reactive protein levels. Eur J Clin Nutr. 2015 Nov;69(11):1209-14. Epub 2015 Apr 1.

Magosso E, Ansari MA, Gopalan Y, et al. Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial. Nutr J. 2013 Dec 27;12(1):166.

Patel V, Rink C, Gordillo GM, et al. Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J Nutr. 2012 Mar;142(3):513-9. Epub 2012 Feb 1.

Nesaretnam K, Selvaduray KR, Abdul Razak G, Veerasenan SD, Gomez PA. Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial. Breast Cancer Res. 2010;12(5):R81. Epub 2010 Oct 8.

Khoo TL, Halim AS, Zakaria Z, Mat Saad AZ, Wu LY, Lau HY. A prospective, randomised, double-blinded trial to study the efficacy of topical tocotrienol in the prevention of hypertrophic scars. J Plast Reconstr Aesthet Surg. 2011 Jun;64(6):e137-45. Epub 2010 Sep 24.

Cheishvili D, Maayan C, Holzer N, et al. Tocotrienol Treatment in Familial Dysautonomia: Open-Label Pilot Study. J Mol Neurosci. 2016 Jul;59(3):382-91. Epub 2016 Apr 30.